Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease

Authors not listed

Hillel Grossman · 2018

Dysbiosis Human Randomized controlled trial

Abstract

Alzheimer Disease (AD) is a progressive brain disease generally known as senile dementia. Our proposed study will establish safety and pharmacokinetics of Meganatural-AZ GSPE in AD subjects. As secondary measures, we will also provide the essential human data to guide the design of future studies to test the efficacy of GSPE in mitigating cognitive deterioration in AD patients.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-26 MST

Cite this

APA

Anonymous. (2018). Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease. <em>Hillel Grossman</em>. https://clinicaltrials.gov/study/NCT02033941

Vancouver

Anonymous. Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease. Hillel Grossman. 2018.

BibTeX

@misc{anon2018PhaseI, title = {Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease}, author = {Anonymous}, journal = {Hillel Grossman}, year = {2018}, }